Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

Fig. 6

Associations between PTPRD mutation and TMB, PD-L1 expression. a, e TMB of WT, other-mut, phosphatase-mut group in discovery cohort (a), validation cohort 1 (b), validation cohort 2 (c), validation cohort 3 (d), and TCGA-LUAD cohort (e). f, i PD-L1 expression of WT, other-mut, and phosphatase-mut group in discovery cohort (f), validation cohort 1 (g), validation cohort 3 (h), and TCGA-LUAD cohort (i). j–l Forest plots of univariate and multivariate cox regression analysis of merged cohort of discovery and validation cohort 1 (j), validation cohort 3 (k), and validation cohort 2 (l). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; n.s., no significance

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us